Ascentage Pharma Group International (NASDAQ:AAPG) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $48.00 target price on the stock.

Other equities analysts also recently issued reports about the stock. BTIG Research began coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 target price on the stock. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a research note on Monday, November 24th. Piper Sandler initiated coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 target price for the company. Finally, Oppenheimer started coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Ascentage Pharma Group International has a consensus rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Stock Performance

Shares of AAPG opened at $27.77 on Tuesday. The company’s fifty day moving average is $29.97 and its 200-day moving average is $36.01. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. Ascentage Pharma Group International has a 12 month low of $16.50 and a 12 month high of $48.45.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG raised its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter. XY Capital Ltd increased its holdings in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period. Tema Etfs LLC acquired a new position in shares of Ascentage Pharma Group International during the second quarter valued at about $610,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the third quarter worth about $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.